-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Atrial fibrillation (AF), the most common cardiac arrhythmia , is associated with a 5-fold increased risk of stroke
, a common subsequent cause of dementia .
However, there is growing evidence of an association between AF and dementia, even in patients without a history of ischemic stroke
arrhythmia stroke _
Researchers compared the incidence of dementia between oral anticoagulant (OAC) users and non-users in a large cohort of primary care patients with atrial fibrillation
.
The researchers conducted a retrospective study using Medicine Insight, an Australia-wide primary care dataset
.
We included patients aged ≥18 years with newly diagnosed atrial fibrillation between January 1, 2010, and December 31, 2017, and no history of dementia or stroke, and followed up until December 31, 2018
diagnosis
During a mean follow-up of 3.
7±2.
0 years, 425 patients (2.
3%; 95% CI, 2.
1%-2.
5%) had a documented diagnosis of dementia
.
After propensity matching, OAC users had a significantly lower incidence of dementia compared with non-users (hazard ratio [HR], 0.
CONCLUSIONS: In patients with atrial fibrillation, the use of OAC may reduce the incidence of dementia compared with treatment with warfarin or no anticoagulant
.
.
Original source:
Original source:Woldesellassie M.
Oral Anticoagulant Treatment and the Risk of Dementia in Patients With Atrial Fibrillation: A Population‐Based Cohort StudyLeave a Comment here
